As a result, tiny compounds functioning as controlling the NF-κB-mediated proteasome inhibition, such as celastrol and curcumin, can be applied to target the ubiquitin–proteasome system (UPS), then affecting NF-κB signaling to provide another reasonable method for prophylaxis and therapy of COVID-19 patients. Here, NFKB1 is linked to COVID-19.